Ozempic vs Wegovy: Which GLP-1 is Right for You?
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 5, 2026
Last Reviewed
Mar 14, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Key Takeaways
- •Both Ozempic and Wegovy contain semaglutide — the same active ingredient — but at different approved doses and FDA indications.
- •Wegovy is FDA-approved for weight loss (BMI ≥ 30 or ≥ 27 with comorbidity) at up to 2.4mg/week; Ozempic is approved for type 2 diabetes at up to 2mg/week.
- •Wegovy produces more weight loss (average 14.9% of body weight) because it's dosed higher than Ozempic (average 9–11%).
- •Insurance coverage differs significantly: Ozempic has broader coverage as a diabetes drug; Wegovy faces more prior authorization hurdles for obesity.
- •If you have type 2 diabetes and obesity, your doctor may prefer Ozempic — if you have obesity without diabetes, Wegovy is the on-label choice.
Ozempic vs Wegovy: Key Differences at a Glance
Ozempic and Wegovy both contain semaglutide, but they are FDA-approved for different conditions at different doses. Ozempic (max 2.0mg/week) is approved for Type 2 diabetes. Wegovy (max 2.4mg/week) is approved for chronic weight management. Both are made by Novo Nordisk. The 0.4mg dose difference matters — semaglutide's weight-loss effect increases sharply in the 1.7–2.4mg range, and the STEP trials consistently showed the 2.4mg dose produced substantially greater weight loss than lower doses. To understand how GLP-1 works at the molecular level, read our complete guide to GLP-1 mechanisms.
Key Differences
Ozempic is FDA-approved specifically for type 2 diabetes, with a maximum weekly dose of 2.0mg. Wegovy is FDA-approved for chronic weight management, with a higher maximum dose of 2.4mg weekly. The 0.4mg difference is more significant than it sounds — the dose-response curve for weight loss with semaglutide is steep in the 1.7–2.4mg range, and the STEP trials consistently showed the 2.4mg dose produced substantially greater weight loss.
Side Effects Comparison
Because both drugs contain semaglutide, their side effect profiles are nearly identical. Nausea is the most commonly reported issue, especially during dose escalation. The higher 2.4mg maintenance dose in Wegovy may produce slightly more pronounced gastrointestinal discomfort compared to the 2.0mg ceiling of Ozempic. Starting low and titrating slowly is the standard clinical approach for both.
Insurance and Cost
Insurance coverage often dictates which medication a patient receives. Many plans cover Ozempic for diabetes but may require a prior authorization. Wegovy coverage varies significantly by employer plan, as weight loss medications are frequently excluded from standard formularies. Without insurance, Wegovy runs approximately $1,349/month while Ozempic runs approximately $935/month.
Which Should You Choose?
Your healthcare provider will prescribe the appropriate medication based on your diagnosis. If you have type 2 diabetes, Ozempic is the standard on-label path. If your primary goal is weight loss and you do not have diabetes, Wegovy is the FDA-indicated choice. Patients with obesity and established cardiovascular disease now have a compelling case for Wegovy thanks to the SELECT trial's 20% cardiovascular event reduction finding. Never substitute one for the other without medical supervision.
GLP-1 Drug Price Comparison
Updated March 2026 · Prices shown are average monthly retail costs. Actual costs vary by pharmacy and insurance plan.
| Drug | Indication | Admin | Without Insurance | With Insurance | Avg. Weight Loss | |
|---|---|---|---|---|---|---|
WegovyMost Popular Novo Nordisk | Weight Loss | Weekly Injection | $1,349/mo | $25–$200/mo | ~15–20% | Check Price |
Ozempic Novo Nordisk | Type 2 Diabetes | Weekly Injection | $935/mo | $25–$150/mo | ~12–15% | Check Price |
ZepboundBest Results Eli Lilly | Weight Loss | Weekly Injection | $1,059/mo | $25–$175/mo | ~20–22% | Check Price |
Mounjaro Eli Lilly | Type 2 Diabetes | Weekly Injection | $1,069/mo | $25–$150/mo | ~18–20% | Check Price |
RybelsusNeedle-Free Novo Nordisk | Type 2 Diabetes | Daily Pill | $850/mo | $10–$100/mo | ~5–8% | Check Price |
Without insurance
$1,349/mo
With insurance
$25–$200/mo
Avg. weight loss
~15–20%
Administration
Weekly Injection
Without insurance
$935/mo
With insurance
$25–$150/mo
Avg. weight loss
~12–15%
Administration
Weekly Injection
Without insurance
$1,059/mo
With insurance
$25–$175/mo
Avg. weight loss
~20–22%
Administration
Weekly Injection
Without insurance
$1,069/mo
With insurance
$25–$150/mo
Avg. weight loss
~18–20%
Administration
Weekly Injection
Without insurance
$850/mo
With insurance
$10–$100/mo
Avg. weight loss
~5–8%
Administration
Daily Pill
* Prices are estimates based on average pharmacy retail pricing. Always verify with your pharmacy or insurance. Some links are affiliate links — we may earn a commission at no extra cost to you.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
